Literature DB >> 23744077

Anti-HIV host factor SAMHD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels.

Sarah M Amie1, Michele B Daly, Erin Noble, Raymond F Schinazi, Robert A Bambara, Baek Kim.   

Abstract

Newly identified anti-HIV host factor, SAMHD1, restricts replication of lentiviruses such as HIV-1, HIV-2, and simian immunodeficiency virus in macrophages by enzymatically hydrolyzing and depleting cellular dNTPs, which are the substrates of viral DNA polymerases. HIV-2 and some simian immunodeficiency viruses express viral protein X (VPX), which counteracts SAMHD1 and elevates cellular dNTPs, enhancing viral replication in macrophages. Because nucleoside reverse transcriptase inhibitors (NRTIs), the most commonly used anti-HIV drugs, compete against cellular dNTPs for incorporation into proviral DNA, we tested whether SAMHD1 directly affects the efficacy of NRTIs in inhibiting HIV-1. We found that reduction of SAMHD1 levels with the use of virus-like particles expressing Vpx- and SAMHD1-specific shRNA subsequently elevates cellular dNTPs and significantly decreases HIV-1 sensitivity to various NRTIs in macrophages. However, virus-like particles +Vpx treatment of activated CD4(+) T cells only minimally reduced NRTI efficacy. Furthermore, with the use of HPLC, we could not detect SAMHD1-mediated hydrolysis of NRTI-triphosphates, verifying that the reduced sensitivity of HIV-1 to NRTIs upon SAMHD1 degradation is most likely caused by the elevation in cellular dNTPs.

Entities:  

Keywords:  DNA Polymerase; DNA Replication; HIV-1; Macrophages; Nucleoside Nucleotide Analogs

Mesh:

Substances:

Year:  2013        PMID: 23744077      PMCID: PMC3711331          DOI: 10.1074/jbc.M113.472159

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Antiretroviral therapy in macrophages: implication for HIV eradication.

Authors:  Christina Gavegnano; Raymond F Schinazi
Journal:  Antivir Chem Chemother       Date:  2009-10-19

Review 2.  Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.

Authors:  S Aquaro; C F Perno; E Balestra; J Balzarini; A Cenci; M Francesconi; S Panti; F Serra; N Villani; R Caliò
Journal:  J Leukoc Biol       Date:  1997-07       Impact factor: 4.962

3.  Ovine lentivirus-infected macrophages mediate productive infection in cell types that are not susceptible to infection with cell-free virus.

Authors:  D K Singh; Y Chebloune; L Mselli-Lakhal; B M Karr; O Narayan
Journal:  J Gen Virol       Date:  1999-06       Impact factor: 3.891

4.  Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase.

Authors:  Tracy L Diamond; Mikhail Roshal; Varuni K Jamburuthugoda; Holly M Reynolds; Aaron R Merriam; Kwi Y Lee; Mini Balakrishnan; Robert A Bambara; Vicente Planelles; Stephen Dewhurst; Baek Kim
Journal:  J Biol Chem       Date:  2004-09-26       Impact factor: 5.157

Review 5.  Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

Authors:  Erik De Clercq
Journal:  Int J Antimicrob Agents       Date:  2008-12-23       Impact factor: 5.283

6.  Genetic selection in Escherichia coli for active human immunodeficiency virus reverse transcriptase mutants.

Authors:  B Kim
Journal:  Methods       Date:  1997-08       Impact factor: 3.608

7.  Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.

Authors:  David Marchant; Stuart J D Neil; Áine McKnight
Journal:  J Gen Virol       Date:  2006-02       Impact factor: 3.891

8.  SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells.

Authors:  Caroline Goujon; Lise Rivière; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  Retrovirology       Date:  2007-01-09       Impact factor: 4.602

9.  HIV infection of non-dividing cells: a divisive problem.

Authors:  Ariberto Fassati
Journal:  Retrovirology       Date:  2006-10-26       Impact factor: 4.602

10.  Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy.

Authors:  Pauline Chugh; Birgit Bradel-Tretheway; Carlos M R Monteiro-Filho; Vicente Planelles; Sanjay B Maggirwar; Stephen Dewhurst; Baek Kim
Journal:  Retrovirology       Date:  2008-01-31       Impact factor: 4.602

View more
  31 in total

1.  Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells.

Authors:  Joseph A Hollenbaugh; Susan M Schader; Raymond F Schinazi; Baek Kim
Journal:  Virology       Date:  2015-08-29       Impact factor: 3.616

Review 2.  Deoxyribonucleotides as genetic and metabolic regulators.

Authors:  Christopher K Mathews
Journal:  FASEB J       Date:  2014-06-13       Impact factor: 5.191

3.  SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors.

Authors:  Andrew D Huber; Eleftherios Michailidis; Megan L Schultz; Yee T Ong; Nicolin Bloch; Maritza N Puray-Chavez; Maxwell D Leslie; Juan Ji; Anthony D Lucas; Karen A Kirby; Nathaniel R Landau; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  GTP is the primary activator of the anti-HIV restriction factor SAMHD1.

Authors:  Sarah M Amie; Robert A Bambara; Baek Kim
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

5.  Novel inhibitors of human immunodeficiency virus type 2 infectivity.

Authors:  Lauren B Beach; Jonathan M Rawson; Baek Kim; Steven E Patterson; Louis M Mansky
Journal:  J Gen Virol       Date:  2014-08-07       Impact factor: 3.891

Review 6.  SAMHD1: Recurring roles in cell cycle, viral restriction, cancer, and innate immunity.

Authors:  Christopher H Mauney; Thomas Hollis
Journal:  Autoimmunity       Date:  2018-03-27       Impact factor: 2.815

7.  SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors.

Authors:  Ester Ballana; Roger Badia; Gerard Terradas; Javier Torres-Torronteras; Alba Ruiz; Eduardo Pauls; Eva Riveira-Muñoz; Bonaventura Clotet; Ramon Martí; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

8.  The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.

Authors:  Kirsten M Knecht; Olga Buzovetsky; Constanze Schneider; Dominique Thomas; Vishok Srikanth; Lars Kaderali; Florentina Tofoleanu; Krystle Reiss; Nerea Ferreirós; Gerd Geisslinger; Victor S Batista; Xiaoyun Ji; Jindrich Cinatl; Oliver T Keppler; Yong Xiong
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-10       Impact factor: 11.205

9.  Identification of Inhibitors of the dNTP Triphosphohydrolase SAMHD1 Using a Novel and Direct High-Throughput Assay.

Authors:  Christopher H Mauney; Fred W Perrino; Thomas Hollis
Journal:  Biochemistry       Date:  2018-11-13       Impact factor: 3.162

10.  Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance.

Authors:  Matilda Rentoft; Kristoffer Lindell; Phong Tran; Anna Lena Chabes; Robert J Buckland; Danielle L Watt; Lisette Marjavaara; Anna Karin Nilsson; Beatrice Melin; Johan Trygg; Erik Johansson; Andrei Chabes
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.